Literature DB >> 20537791

Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach.

Pouneh Dokouhaki1, Mei Han, Betty Joe, Ming Li, Michael R Johnston, Ming-Sound Tsao, Li Zhang.   

Abstract

gammadelta T cells can be an option for adoptive immunotherapy of cancer. The major obstacle to clinical application of gammadelta T cells is their low number and lack of a reliable method to expand them consistently and efficiently. We were able to expand gammadelta T cells with high purity in all donors regardless of their starting repertoire of gammadelta T cells. These ex vivo expanded gammadelta T cells are in early differentiation stage, can efficiently kill various tumors and inhibit growth of human lung cancer xenografts. This new approach for ex vivo expansion of human gammadelta T cells will open new horizons for clinical use of these cells. 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20537791     DOI: 10.1016/j.canlet.2010.05.005

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  22 in total

1.  Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor.

Authors:  Drew C Deniger; Kirsten Switzer; Tiejuan Mi; Sourindra Maiti; Lenka Hurton; Harjeet Singh; Helen Huls; Simon Olivares; Dean A Lee; Richard E Champlin; Laurence J N Cooper
Journal:  Mol Ther       Date:  2013-01-08       Impact factor: 11.454

Review 2.  Role of gamma-delta T-cells in cancer: another opening door to immunotherapy.

Authors:  Diego Marquez-Medina; Joel Salla-Fortuny; Antonieta Salud-Salvia
Journal:  Clin Transl Oncol       Date:  2012-10-02       Impact factor: 3.405

3.  Modulation of γδ T-cell activation by neutrophil elastase.

Authors:  Nadia Yasmín Towstyka; Carolina Maiumi Shiromizu; Irene Keitelman; Florencia Sabbione; Gabriela Verónica Salamone; Jorge Raúl Geffner; Analía Silvina Trevani; Carolina Cristina Jancic
Journal:  Immunology       Date:  2017-10-05       Impact factor: 7.397

4.  Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies.

Authors:  Jianhua Zhou; Ning Kang; Lianxian Cui; Denian Ba; Wei He
Journal:  Cell Mol Immunol       Date:  2011-06-13       Impact factor: 11.530

5.  Ex vivo expanded human circulating Vδ1 γδT cells exhibit favorable therapeutic potential for colon cancer.

Authors:  Dang Wu; Pin Wu; Xianguo Wu; Jun Ye; Zhen Wang; Shuai Zhao; Chao Ni; Guoming Hu; Jinghong Xu; Yuehua Han; Ting Zhang; Fuming Qiu; Jun Yan; Jian Huang
Journal:  Oncoimmunology       Date:  2015-01-22       Impact factor: 8.110

6.  A new effect of IL-4 on human γδ T cells: promoting regulatory Vδ1 T cells via IL-10 production and inhibiting function of Vδ2 T cells.

Authors:  Yujia Mao; Shanshan Yin; Jianmin Zhang; Yu Hu; Bo Huang; Lianxian Cui; Ning Kang; Wei He
Journal:  Cell Mol Immunol       Date:  2015-03-16       Impact factor: 11.530

7.  Differential requirements of CD4(+) T-cell signals for effector cytotoxic T-lymphocyte (CTL) priming and functional memory CTL development at higher CD8(+) T-cell precursor frequency.

Authors:  Channakeshava S Umeshappa; Roopa H Nanjundappa; Yufeng Xie; Andrew Freywald; Qingyong Xu; Jim Xiang
Journal:  Immunology       Date:  2013-04       Impact factor: 7.397

8.  Human Vδ2 versus non-Vδ2 γδ T cells in antitumor immunity.

Authors:  Dieter Kabelitz; Shirin Kalyan; Hans-Heinrich Oberg; Daniela Wesch
Journal:  Oncoimmunology       Date:  2013-03-01       Impact factor: 8.110

9.  Anti-leukemia activity of in vitro-expanded human gamma delta T cells in a xenogeneic Ph+ leukemia model.

Authors:  Gabrielle M Siegers; Tania C Felizardo; A Mark Mathieson; Yoko Kosaka; Xing-Hua Wang; Jeffrey A Medin; Armand Keating
Journal:  PLoS One       Date:  2011-02-03       Impact factor: 3.240

10.  Abnormal expression levels of sMICA and NKG2D are correlated with poor prognosis in pancreatic cancer.

Authors:  Jiong Chen; Hong Xu; Xing-Xing Zhu
Journal:  Ther Clin Risk Manag       Date:  2015-12-22       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.